vs
Side-by-side financial comparison of Biogen (BIIB) and Dominion Energy (D). Click either name above to swap in a different company.
Dominion Energy is the larger business by last-quarter revenue ($4.2B vs $2.3B, roughly 1.8× Biogen). Dominion Energy runs the higher net margin — 13.9% vs -2.1%, a 16.1% gap on every dollar of revenue. On growth, Dominion Energy posted the faster year-over-year revenue change (23.2% vs -7.1%). Over the past eight quarters, Dominion Energy's revenue compounded faster (9.3% CAGR vs -0.2%).
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for ...
Dominion Energy, Inc., commonly referred to as Dominion, is an American energy company headquartered in Richmond, Virginia that supplies electricity in parts of Virginia, North Carolina, and South Carolina and supplies natural gas to parts of Utah, Idaho and Wyoming, West Virginia, Ohio, Pennsylvania, North Carolina, South Carolina, and Georgia. Dominion also has generation facilities in Indiana, Illinois, Connecticut, and Rhode Island.
BIIB vs D — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3B | $4.2B |
| Net Profit | $-48.9M | $586.0M |
| Gross Margin | 78.3% | — |
| Operating Margin | -2.5% | 18.0% |
| Net Margin | -2.1% | 13.9% |
| Revenue YoY | -7.1% | 23.2% |
| Net Profit YoY | -118.3% | 871.1% |
| EPS (diluted) | $-0.35 | $0.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3B | $4.2B | ||
| Q3 25 | $2.5B | $4.5B | ||
| Q2 25 | $2.6B | $3.7B | ||
| Q1 25 | $2.4B | $4.1B | ||
| Q4 24 | $2.5B | $3.4B | ||
| Q3 24 | $2.5B | $3.8B | ||
| Q2 24 | $2.5B | $3.5B | ||
| Q1 24 | $2.3B | $3.5B |
| Q4 25 | $-48.9M | $586.0M | ||
| Q3 25 | $466.5M | $1.0B | ||
| Q2 25 | $634.8M | $760.0M | ||
| Q1 25 | $240.5M | $646.0M | ||
| Q4 24 | $266.7M | $-76.0M | ||
| Q3 24 | $388.5M | $954.0M | ||
| Q2 24 | $583.6M | $572.0M | ||
| Q1 24 | $393.4M | $674.0M |
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -2.5% | 18.0% | ||
| Q3 25 | 22.0% | 29.7% | ||
| Q2 25 | 28.1% | 29.5% | ||
| Q1 25 | 12.8% | 29.9% | ||
| Q4 24 | 11.9% | 11.4% | ||
| Q3 24 | 18.3% | 32.2% | ||
| Q2 24 | 28.3% | 23.3% | ||
| Q1 24 | 20.3% | 23.6% |
| Q4 25 | -2.1% | 13.9% | ||
| Q3 25 | 18.4% | 22.3% | ||
| Q2 25 | 24.0% | 20.4% | ||
| Q1 25 | 9.9% | 15.8% | ||
| Q4 24 | 10.9% | -2.2% | ||
| Q3 24 | 15.8% | 25.2% | ||
| Q2 24 | 23.7% | 16.6% | ||
| Q1 24 | 17.2% | 19.1% |
| Q4 25 | $-0.35 | $0.66 | ||
| Q3 25 | $3.17 | $1.16 | ||
| Q2 25 | $4.33 | $0.88 | ||
| Q1 25 | $1.64 | $0.75 | ||
| Q4 24 | $1.82 | $-0.11 | ||
| Q3 24 | $2.66 | $1.12 | ||
| Q2 24 | $4.00 | $0.65 | ||
| Q1 24 | $2.70 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $250.0M |
| Total DebtLower is stronger | $6.3B | $44.1B |
| Stockholders' EquityBook value | $18.3B | $29.1B |
| Total Assets | $29.4B | $115.9B |
| Debt / EquityLower = less leverage | 0.34× | 1.52× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $250.0M | ||
| Q3 25 | — | $932.0M | ||
| Q2 25 | — | $344.0M | ||
| Q1 25 | — | $355.0M | ||
| Q4 24 | — | $310.0M | ||
| Q3 24 | — | $1.8B | ||
| Q2 24 | — | $139.0M | ||
| Q1 24 | — | $265.0M |
| Q4 25 | $6.3B | $44.1B | ||
| Q3 25 | $6.3B | $43.3B | ||
| Q2 25 | $6.3B | $40.3B | ||
| Q1 25 | $4.5B | $39.9B | ||
| Q4 24 | $6.3B | $37.5B | ||
| Q3 24 | $4.5B | $37.1B | ||
| Q2 24 | $6.3B | $36.6B | ||
| Q1 24 | $6.3B | $35.1B |
| Q4 25 | $18.3B | $29.1B | ||
| Q3 25 | $18.2B | $27.7B | ||
| Q2 25 | $17.6B | $27.2B | ||
| Q1 25 | $17.0B | $27.4B | ||
| Q4 24 | $16.7B | $27.3B | ||
| Q3 24 | $16.4B | $27.5B | ||
| Q2 24 | $15.9B | $27.1B | ||
| Q1 24 | $15.2B | $27.4B |
| Q4 25 | $29.4B | $115.9B | ||
| Q3 25 | $29.2B | $111.6B | ||
| Q2 25 | $28.3B | $107.4B | ||
| Q1 25 | $28.0B | $104.6B | ||
| Q4 24 | $28.0B | $102.4B | ||
| Q3 24 | $28.3B | $99.8B | ||
| Q2 24 | $26.8B | $100.4B | ||
| Q1 24 | $26.6B | $102.0B |
| Q4 25 | 0.34× | 1.52× | ||
| Q3 25 | 0.35× | 1.56× | ||
| Q2 25 | 0.36× | 1.48× | ||
| Q1 25 | 0.27× | 1.46× | ||
| Q4 24 | 0.38× | 1.38× | ||
| Q3 24 | 0.28× | 1.35× | ||
| Q2 24 | 0.40× | 1.35× | ||
| Q1 24 | 0.41× | 1.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $511.9M | $987.0M |
| Free Cash FlowOCF − Capex | $468.0M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | — | 1.68× |
| TTM Free Cash FlowTrailing 4 quarters | $2.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $511.9M | $987.0M | ||
| Q3 25 | $1.3B | $1.9B | ||
| Q2 25 | $160.9M | $1.2B | ||
| Q1 25 | $259.3M | $1.2B | ||
| Q4 24 | $760.9M | $641.0M | ||
| Q3 24 | $935.6M | $1.5B | ||
| Q2 24 | $625.8M | $856.0M | ||
| Q1 24 | $553.2M | $2.0B |
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — | ||
| Q1 24 | $507.3M | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 22.1% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 2.0% | — |
| Q4 25 | — | 1.68× | ||
| Q3 25 | 2.73× | 1.93× | ||
| Q2 25 | 0.25× | 1.64× | ||
| Q1 25 | 1.08× | 1.83× | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 2.41× | 1.61× | ||
| Q2 24 | 1.07× | 1.50× | ||
| Q1 24 | 1.41× | 2.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
D
| Dominion Energy Virginia | $3.0B | 72% |
| Nonregulated Electricity Sales | $334.0M | 8% |
| Contracted Energy | $306.0M | 7% |
| Other | $292.0M | 7% |
| Other Nonregulated Revenues | $97.0M | 2% |
| Other Regulated Revenues | $66.0M | 2% |
| Alternative Revenue Programs | $50.0M | 1% |
| Transition Services Agreements | $25.0M | 1% |
| Regulated Gas Transportation And Storage | $10.0M | 0% |
| Related Party | $5.0M | 0% |
